2021 Targeted Therapies of Lung Cancer (TTLC) Meeting - Posters-P09. EGFR-TKIs Associated Cardiotoxicity in Lung Cancer Patients: An Analysis of FAERS Database

P09. EGFR-TKIs Associated Cardiotoxicity in Lung Cancer Patients: An Analysis of FAERS Database - PDF

Pdf Summary

Researchers from China conducted an analysis of the US Food and Drug Administration (FDA) Adverse Reporting System (FAERS) database to investigate the cardiotoxicity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung cancer patients. EGFR-TKIs, such as gefitinib, erlotinib, afatinib, and osimertinib, have been shown to improve the survival of lung cancer patients with EGFR mutations. However, there have been limited large-scale studies on the cardiotoxicities associated with these drugs. The study included 17,261 lung cancer patients who experienced adverse events related to EGFR-TKIs between 2016 and 2020. <br /><br />The results showed that out of the total 9,577 adverse events associated with TKIs, 495 (5.2%) were cardiac disorders. Advanced age, treatment with osimertinib, and treatment with combined types of TKIs were positively associated with the incidence of cardiac adverse events. There was no significant association between the incidence of cardiac adverse events and the histology of lung cancer. Compared to other TKIs, patients who received osimertinib had an increased risk of cardiac failure and QT prolongation. However, there were no significant differences in the risk of myocardial infarction, atrial fibrillation, and pericardial effusion.<br /><br />The study concluded that older patients and those who received osimertinib and a combination of TKIs had an increased risk of cardiac adverse events, particularly cardiac failure and QT prolongation. The researchers emphasized the importance of healthcare professionals being aware of the cardiotoxicity of EGFR-TKIs and early identification and intervention of cardiac adverse events. They also recommended consulting cardiologists when necessary to manage these problems.

Asset Subtitle

Dongchen Sun

Meta Tag

Speaker Dongchen Sun

Topic Targeted Therapies - EGFR

Keywords

China

researchers

FDA

FAERS

cardiotoxicity

EGFR-TKIs

lung cancer

adverse events

osimertinib

cardiac disorders